Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M. Krupka C, et al. Among authors: subklewe m. Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060. Oncotarget. 2017. PMID: 28415689 Free PMC article.
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M. Krupka C, et al. Among authors: subklewe m. Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3. Blood. 2014. PMID: 24300852 Free article.
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H. Janke H, et al. Among authors: subklewe m. PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. eCollection 2014. PLoS One. 2014. PMID: 24608088 Free PMC article.
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.
Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K. Hubmann M, et al. Among authors: subklewe m. Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9. Haematologica. 2014. PMID: 24816240 Free PMC article. Clinical Trial.
Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.
Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A. Witter K, et al. Among authors: subklewe m. Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345. Epub 2014 Apr 3. Bone Marrow Res. 2014. PMID: 24860670 Free PMC article.
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M. Köhnke T, et al. Among authors: subklewe m. Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10. Leukemia. 2015. PMID: 24912430
200 results